Replies to post #206558 on Biotech Values

[DewDiligence]

ABIO -62% on failed phase-2b for Gencaro in AF:

https://finance.yahoo.com/news/arca-biopharma-reports-topline-phase-130000918.html

ARCA biopharma…today announced clinical results from GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

… In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, TOPROL-XL (143 total events, hazard ratio of 1.01 (95% confidence interval: 0.71, 1.42)…

The primary endpoint was time to recurrence of AF.